@article{APS10307,
author = {Shu Liu and He Huang and Rong-xin Chen and Zhao Wang and Yan-ping Guan and Chen Peng and Xiao-jie Fang and Zhuo-jia Chen and Shao-xing Guan and Xia Zhu and Quan-guang Ren and Yu-yi Yao and Hong-bing Huang and Min Huang and Xue-ding Wang and Tong-yu Lin},
title = {Low initial trough concentration of rituximab is associated with unsatisfactory response of first-line R-CHOP treatment in patients with follicular lymphoma with grade 1/2},
journal = {Acta Pharmacologica Sinica},
volume = {42},
number = {4},
year = {2021},
keywords = {},
abstract = {For follicular lymphoma (FL) with grade 1/2, the complete response (CR) rate of the first-line R-CHOP treatment was significantly low. In this study, we assessed the rationality of the administration of rituximab for FL patients with grade 1/2 based on concentration–response relationship analyses. Thus, we conducted a prospective pharmacokinetic (PK) study in 68 FL patients with grades 1–3 treated with R-CHOP at 21-day intervals. Plasma rituximab concentrations were quantified using ELISA and the population PK modeling was established with Phoenix® NLMETM. The first cycle trough concentration (C1-trough) of rituximab was a significant independent risk factor for achieving CR in matched-pair logistic regression analysis, rather than the concentrations in later cycles; the recommendatory minimum optimal C1-trough was 13.60 μg/mL. Patients with grade 1/2 had significantly lower C1-trough compared with grade 3 (12.21 μg/mL vs. 23.45 μg/mL, P },
issn = {1745-7254}, url = {http://www.chinaphar.com/article/view/10307}
}